A phase II study of SGN-40 (anti-huCD40 mAb) in patients with relapsed diffuse large B-cell lymphoma (DLBCL)

Trial Profile

A phase II study of SGN-40 (anti-huCD40 mAb) in patients with relapsed diffuse large B-cell lymphoma (DLBCL)

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Mar 2015

At a glance

  • Drugs Dacetuzumab (Primary)
  • Indications Diffuse large B cell lymphoma
  • Focus Therapeutic Use
  • Sponsors Seattle Genetics
  • Most Recent Events

    • 16 Jun 2009 Actual end date (Jan 2009) added as reported by ClinicalTrials.gov.
    • 16 Jun 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 12 Oct 2008 1 Dec 2008 added as the planned end date based on information from ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top